Does Uncle Sam have designs on Scancell?
Posted: Thu Mar 06, 2014 9:32 am
Its no secret, Scancell's directors plan to sell the British company sometime over the next few years. The Americans are probably the most interested of all in seeing the company cross the Atlantic as Scancell has been given the worldwide rights to use the US Department of Health's melanoma antigens in its lead vaccine, SCIB1. The US government can only get a return on these antigen discoveries when Scancell's vaccine enters the market-place. Scancell has agreed to pay royalties, which the Americans are keen to receive having spent years and millions of dollars developing the antigens at the National Cancer Institute in Bethesda, Maryland.
Here's an intriguing comment by one poster on London South East's Scancell Chat:
Politics! Politics!
The US government owns the melanoma antigens in Scancell's lead vaccine. To get a return on the millions of dollars they have spent developing them, they will be putting enormous pressure on American drug suppliers to government health programs to buy up Scancell quickly. Scancell has been smart: having got the worldwide rights to exploit the antigens commercially they rushed to get a composition of matter patent for the vaccine and a US patent over its DNA delivery. This has prevented any other company from using the antigens unless they buy Scancell first. I expect a major US company will end up owning Scancell now. There is no way the Americans will relinquish final ownership of their discoveries.
As a footnote to the above: on 11th February 2014 the U. S. Food and Drug Administration (FDA) granted the coveted Orphan Drug Designation to Scancell's SCIB1 ImmunoBody® vaccine for the treatment of metastatic melanoma.
Here's some research and fact checking links:
13th May 2010
Licensing agreement with the U.S. National Institutes of Health.
http://www.scancell.co.uk/Apps/Content/News/?id=186
20th October 2011
Composition of matter patent granted for SCIB1.
http://www.scancell.co.uk/Apps/Content/News/?id=222
9th March 2012
ImmunoBody® vaccine patent approved in the United States.
http://www.scancell.co.uk/Apps/Content/News/?id=244
11th February 2014
SCIB1 Granted FDA Orphan Drug Status
http://www.scancell.co.uk/Apps/Content/News/?id=313
Here's an intriguing comment by one poster on London South East's Scancell Chat:
Politics! Politics!
The US government owns the melanoma antigens in Scancell's lead vaccine. To get a return on the millions of dollars they have spent developing them, they will be putting enormous pressure on American drug suppliers to government health programs to buy up Scancell quickly. Scancell has been smart: having got the worldwide rights to exploit the antigens commercially they rushed to get a composition of matter patent for the vaccine and a US patent over its DNA delivery. This has prevented any other company from using the antigens unless they buy Scancell first. I expect a major US company will end up owning Scancell now. There is no way the Americans will relinquish final ownership of their discoveries.
As a footnote to the above: on 11th February 2014 the U. S. Food and Drug Administration (FDA) granted the coveted Orphan Drug Designation to Scancell's SCIB1 ImmunoBody® vaccine for the treatment of metastatic melanoma.
Here's some research and fact checking links:
13th May 2010
Licensing agreement with the U.S. National Institutes of Health.
http://www.scancell.co.uk/Apps/Content/News/?id=186
20th October 2011
Composition of matter patent granted for SCIB1.
http://www.scancell.co.uk/Apps/Content/News/?id=222
9th March 2012
ImmunoBody® vaccine patent approved in the United States.
http://www.scancell.co.uk/Apps/Content/News/?id=244
11th February 2014
SCIB1 Granted FDA Orphan Drug Status
http://www.scancell.co.uk/Apps/Content/News/?id=313